---
document_datetime: 2025-07-10 15:01:10
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/fymskina-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: fymskina-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.406503
conversion_datetime: 2025-12-22 12:28:48.840438
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Fymskina

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific information after authorisation (archive).

| Applicationnumber    | Scope                               | Opinion/ Notification 1 issued on   | Commission Decision Issued²/ amendedon   | Product Information affected3   | Summary   |
|----------------------|-------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation typeIA_IN/ | B.II.b.2.cReplacementor additionofa | 10/07/2025                          |                                          | Annex II and                    |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),AnnexII,Labelling,PL(PackageLeaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics, annexII, labelling,package leaflet).The CDisissuedwithintwomonths of the opinionforvariationsfallingunderthescope ofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000284868                     | manufacturerresponsibleforimportation and/or batch release - B.1I.b.2.c.1 Not includingbatchcontrol/testing-Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |     | PL          |                                                                                                                                                                                                                                                                                 |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000285202 | B.1.b.2 Change in testprocedure for active substance or starting material/reagent/intermediateusedinthe manufacturing process of the active substance-B.I.b.2.a Minor changes to an approved test procedure - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 08/07/2025 | N/A |             |                                                                                                                                                                                                                                                                                 |
| Variation type IB / EMA/VR/0000266712 | C.1.2Change(s)in theSummary of Product Characteristics,LabellingorPackageLeaflet of ageneric/hybrid/biosimilarmedicinal products following assessment of the same change for the reference product-C.I.2.a Implementationof change(s)forwhichno newadditional dataisrequiredtobe submitted by theMAH-Accepted C.1.2.a -To update section 4.5, 4.8 and 5.2 of the SmPC, to add drug-drug interaction information based on results from study CNTO1275CRD1003(aphase1,open-label, druginteractionstudytoevaluatetheeffect ofustekinumaboncytochromeP450enzyme activitiesfollowinginduction and maintenance dosing in participants with activeCrohn'sdiseaseorulcerativecolitis) and to include patient exposure numbers based on results from study CNTO1275Uc03001(aphase3,randomised, | 19/05/2025 |     | SmPC and PL | Toupdate section 4.5,4.8 and5.2 of theSmPC,to adddrug-druginteractioninformationbased on resultsfrom studyCNTO1275CRD1003and to includepatientexposure numbersbased onresults fromstudyCNTO1275UC03001,followingthe assessmentofthesamechangeforthereference product 'Stelara'. |

<div style=\"page-break-after: always\"></div>

|                                       | double-blind, placebo-controlled, parallel- group, multicentre protocol to evaluate the safety andefficacyofustekinumabinduction and maintenance therapy in subjects with moderatelytoseverelyactiveulcerative colitis),followingtheassessmentofthe samechangeforthereferenceproduct Stelara'.Additionally,the MAH took the opportunity to update the information of the localrepresentativeforDE,thelocal representativeforotherEUcountries，and introducedminoreditorialchangesto thePI inDEtocorrectfortypographicalerrors.   |            |      |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------|
| Variation type IB / EMA/VR/0000248050 | B.II.f.1.bExtensionoftheshelflifeofthe finished product-B.II.f.1.b.5Extension of the shelf-life of a biological/ immunological medicinalproductinaccordancewith an approved stability protocol- Accepted                                                                                                                                                                                                                                                                                                                        | 03/03/2025 | SmPC |